Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
Rhea-AI Summary
Zentalis Pharmaceuticals (Nasdaq: ZNTL) priced an underwritten public offering of 23,000,000 common shares at $3.50 per share, for expected gross proceeds of approximately $80.5 million before fees. All shares are offered by the company, with closing expected on August 17, 2026, subject to customary conditions.
Zentalis granted underwriters a 30-day option to purchase up to 3,450,000 additional shares at the public offering price, less discounts and commissions. According to Zentalis, net proceeds plus existing cash will fund clinical and preclinical work, regulatory filings, manufacturing, companion diagnostics, pre-commercial activities, and general corporate purposes.
Positive
- Gross proceeds ~$80.5 million from offering before fees and expenses
- 23,000,000 new shares priced, with potential 3,450,000-share underwriter option
- Proceeds designated to fund clinical, preclinical, regulatory and manufacturing activities
- Use of an already effective 2025 SEC shelf registration streamlines capital access
Negative
- Issuance of 23,000,000 new shares may dilute existing shareholders
- Additional underwriter option for 3,450,000 shares could further increase share count
News Explained
The priced offering would add gross proceeds before fees while existing cash was $24,783,000 at June 30, 2026.
Zentalis Pharmaceuticals has priced a company-issued offering that is expected to close on
In an underwritten offering, an investment bank buys the securities for resale, so underwriting fees and expenses reduce proceeds below the stated gross amount. The effective shelf registration provides selling capacity, while the prospectus supplement sets the specific offering terms.
The release grants underwriters an option to purchase additional shares at the offering price, but describes that option as potential additional issuance rather than part of the
The latest quarter reported
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | earnings report | Negative | -15.6% | Q2 results included a $42.3 million net loss and clinical program updates |
| Aug 03 | inducement grants | Neutral | +5.0% | Stock options were granted to two newly hired employees under Nasdaq rules |
| Jul 17 | ESMO presentation | Neutral | -2.0% | The company scheduled ovarian cancer data and ASPENOVA trial presentations |
| Jun 01 | inducement grants | Neutral | -0.8% | Two newly hired employees received 191,000 stock options |
| May 27 | leadership appointments | Neutral | +0.8% | Shannon Campbell joined the board and Sarah Kelly became commercial strategy SVP |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed: the Q2 earnings event aligned with a -15.6% move, while other corporate and development announcements produced both positive and negative reactions.
Key Terms
underwritten public offering financial
companion diagnostic medical
shelf registration statement regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the pricing of an underwritten public offering of 23,000,000 shares of its common stock at a public offering price of
The Company intends to use the net proceeds from the offering, together with the Company’s existing cash, cash equivalents and marketable securities, to fund clinical trials, preclinical studies, regulatory filings, manufacturing and the Company’s companion diagnostic in support of its programs, as well as for pre-commercial activities, capital expenditures, working capital and other general corporate purposes.
TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunners for the offering. H.C. Wainwright & Co. is acting as a passive bookrunner for the offering. Rodman & Renshaw LLC is acting as a manager for the offering.
The securities described above are being offered pursuant to an effective shelf registration statement that was filed with the U.S. Securities and Exchange Commission (SEC) on March 26, 2025, and became effective on April 4, 2025. This offering is being made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement.
A final prospectus supplement related to the offering (including the accompanying prospectus) will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement related to the offering and the accompanying prospectus may be obtained, when available, by visiting the SEC’s website or by contacting: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities in this offering in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Certain statements contained in this press release, including, without limitation, those relating to the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering, the anticipated total gross proceeds from the offering, the planned use of proceeds of the offering, the sufficiency of the proceeds of the offering and the Company’s cash, cash equivalents and marketable securities to fund its operating expenses and capital expenditures, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering as well as the anticipated use of proceeds of the offering, general economic conditions and other risks identified from time to time in the reports the Company files with the SEC, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and the final prospectus supplement and accompanying prospectus related to the proposed offering to be filed with the SEC, which are available at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of the statements. The Company’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com
